Stroke treatment - light at the end of the tunnel?
Article Abstract:
Biotechnology firms are moving ahead with new approaches and treatments for ischemic stroke despite the high-profile failures of many stroke drugs in late-stage clinical trials. Firms are pursuing new fibrinolytics to restore blood flow, drugs to protect brain cells from stroke damage and agents to help the brain's natural recovery mechanisms.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
rFactor VIII deficit questioned
Article Abstract:
The National Hemophilia Foundation questions that there is really a shortage of recombinant factor VIII. Some feel that Leverkusen, Germany-based has used the supposed shortage to drive fearful patients into its new, controversial direct purchase program.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Protein C may be sepsis solution
Article Abstract:
Indianapolis, IN-based Eli Lilly plans to submit a biological license application at the beginning of 2001 for its sepsis drug Zovant, recombinant activated protein C. The company will petition the FDA for expedited review.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Ten reasons to turn to the web. The online share dealing revolution. Revealed: UK's best online brokers
- Abstracts: Solving the unit trust selector's dilemma. Henderson Eurotrust
- Abstracts: Packaged deals. Tricks of the trade,
- Abstracts: Investors left counting the cost of Crest. On the Crest of lower charges. Web to slash self-select Isa charges
- Abstracts: Investing in the future. Division: a new dawn. Delcam